A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B
Phase of Trial: Phase I/II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs ABI-H0731 (Primary) ; Entecavir; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 29 Aug 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 05 Jun 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.